Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pembrolizumab, a humanized IgG4 monoclonal antibody targeting programmed death-1 protein, has demonstrated efficacy in relapsed/refractory classical Hodgkin lymphoma (cHL). To assess the complete metabolic response (CMR) rate and safety of pembrolizumab monotherapy in newly diagnosed cHL, we conduct...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Allen, Pamela B., Savas, Hatice, Evens, Andrew M., Advani, Ranjana H., Palmer, Brett, Pro, Barbara, Karmali, Reem, Mou, Eric, Bearden, Jeffrey, Dillehay, Gary, Bayer, Robert A., Eisner, Robert M., Chmiel, Joan S., O’Shea, Kaitlyn, Gordon, Leo I., Winter, Jane N.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2021
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955404/
https://ncbi.nlm.nih.gov/pubmed/32992341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007400
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍